AACR/ASCO Methods in Clinical 2026 Preview

AACR/ASCO Methods in Clinical 2026 is the annual Vail methods workshop for fellows and junior faculty writing IRB-ready oncology protocols. It runs July 26–31, 2026 at The Hythe in Vail, Colorado, with applications already closed after the March 18 deadline.

Key Takeaways

• Dates and site are fixed: July 26–31, 2026 at The Hythe, Vail, Colorado.

• Applications closed March 18, 2026 (1 p.m. ET); acceptance notices were scheduled for late May–early June 2026.

• Planned intake is about 60–65 fellows ($2,500 fee) and about 10–15 junior faculty ($2,900 fee).

• Agenda includes Phase I/II design, correlatives, immunotherapy considerations, and an FDA Project Optimus dose-optimization lecture.

AACR/ASCO Methods Workshop 2026 at a glance

What is AACR/ASCO Methods in Clinical 2026?

It is an intensive, weeklong training program on clinical trial design for therapeutic cancer interventions. AACR describes the audience as clinical fellows and junior faculty across oncology subspecialties, including radiation oncology, surgical oncology, and radiology.

The hallmark deliverable, per the official workshop site, is an institutional review board (IRB)-ready clinical trial protocol with informed consent documents from each participant. That makes the meeting operationally different from a data-readout congress: the product is a protocol, not a late-breaking abstract.

Logistics and faculty listings are published on the AACR 2026 workshop page and mirrored on vailworkshop.org.

Who should BD and clinical development teams watch?

This is not a partnering fair with company booths. The watch list is the cohort of investigators who leave Vail with protocol concepts that may seek industry supply letters, companion diagnostics, or biostatistics support.

Official materials strongly encourage applicants whose protocols use non–FDA-approved agents from a company to upload a letter of commitment (preferred) or at least a letter of intent. Priority scoring favors clear company support. For BD teams, that is the practical signal: protocols that already have supply LOIs are more likely to clear selection and later enter sites.

Eligibility windows are explicit. Fellows must complete fellowship after July 30, 2026. Junior faculty must have finished fellowship between April 30, 2020 and July 26, 2026 and hold Assistant Professor, Instructor, or Lecturer appointments.

What is on the 2026 agenda so far?

The published program remains subject to change, but Monday–Tuesday blocks already name concrete design themes that map to current FDA expectations.

• Phase I trial designs (Shing Lee, Columbia; Patricia M. LoRusso, Yale).

• Phase II designs and objectives (Bora Lim, MD Anderson; Mary W. Redman, Fred Hutchinson).

• Project Optimus: reforming dose optimization and dose selection (Timothy A. Yap).

• Combination and multimodality trials across surgery, radiation, and systemic therapy.

• Biological correlatives, biomarker reproducibility, imaging under targeted therapy/immunotherapy, and immunotherapy study design.

Pre-workshop work starts July 10–24 with a protocol development group introduction. A pretest opens Friday, July 24, due by 5 p.m. Sunday, July 26. Sunday includes Denver airport shuttles, registration, and the welcome overview from the three codirectors.

Why Project Optimus matters for this workshop

Dose selection is no longer a side lecture. FDA’s Oncology Center of Excellence runs Project Optimus to move oncology away from maximum-tolerated-dose defaults toward dosages that balance efficacy, safety, and tolerability.

In August 2024, FDA finalized guidance on optimizing dosage for oncologic drugs and biologics. Sponsors are expected to justify dosages with pharmacokinetics, pharmacodynamics, safety, and exposure-response data, and often to compare more than one dosage before registration trials.

Putting Project Optimus on the Vail Monday agenda means 2026 protocols drafted in the room are being pushed toward those evidence standards. Teams supporting investigator-initiated trials should expect dose-ranging or randomized dosage-evaluation language earlier than they might have five years ago. NCI’s public education on how clinical trials are structured remains a useful primer for non-specialist stakeholders reviewing those protocols.

Costs, lodging, and operational constraints

Selected fellows pay $2,500; junior faculty pay $2,900. Fees cover most workshop meals; participants pay their own air/ground travel and hotel. All attendees must stay at The Hythe for the nights of July 26–31. Workshop materials list a $269 per-night room rate (subject to change) for single occupancy or sharing with a non-participant guest.

Complimentary breakfast and lunch run through the week, with group dinners Sunday–Tuesday and a Friday banquet. Friday dinner is the only event open to families and guests. Roommate matching by preferred gender is available for participants who want a workshop-assigned roommate.

What remains unproven or still in flux

The 2026 detailed lecture grid is “under development” and subject to change. Final accepted-participant lists, exact protocol titles, and any company supply commitments are not public. This preview does not invent readout timelines, stock moves, or deal terms. Track the AACR/ASCO Methods workshop hub and the broader US Events calendar as the program locks.

Related NovaPharma coverage

• FDA Project Optimus and oncology dose optimization

• Clinical trial design trends in oncology 2026

• AACR Annual Meeting 2026 San Diego preview

Frequently Asked Questions

Primary Sources

1. FDA Project Optimus overview

2. FDA guidance: optimizing oncology dosage (August 2024)

3. NCI: what are clinical trials

4. AACR official workshop page (dates, codirectors)

5. Workshop registration, fees, and lodging (2026)